AZD5069 + Enzalutamide 40 MG
Phase 1/2Terminated 1 views this week 0 watching💤 Quiet
Interest: 24/100
24
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration Resistant Prostate Cancer
Conditions
Metastatic Castration Resistant Prostate Cancer
Trial Timeline
Nov 13, 2017 → Nov 16, 2022
NCT ID
NCT03177187About AZD5069 + Enzalutamide 40 MG
AZD5069 + Enzalutamide 40 MG is a phase 1/2 stage product being developed by Astellas Pharma for Metastatic Castration Resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03177187. Target conditions include Metastatic Castration Resistant Prostate Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration Resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03177187 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Metastatic Castration Resistant Prostate Cancer